Cytokinetics EVP Research & Development Fady Ibraham Malik Reports Sale of 3,500 Common Shares for $181,227
- Cytokinetics EVP Research & Development Fady Ibraham Malik sold 3,500 common shares on Nov. 17, 2026.
- Sales comprised 3,300 shares at $51.73 per share and 200 shares at $52.59 per share.
- Malik also exercised non-qualified stock options for 3,500 common shares at $7.8 per share that day.
- His direct common stock holdings totaled 153,902 shares following the transactions, with 9,386 non-qualified stock options remaining.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytokinetics Incorporated published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001061983-26-000114), on November 18, 2026, and is solely responsible for the information contained therein.